Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.

Kommoss S, Gilks CB, Kommoss F, Chow C, Hilpert F, du Bois A, Köbel M, Huntsman DG, Anglesio M, Kalloger SE, Pfisterer J.

Histopathology. 2013 Nov;63(5):704-12. doi: 10.1111/his.12219. Epub 2013 Sep 2.

PMID:
24033430
2.

Calculator for ovarian carcinoma subtype prediction.

Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB.

Mod Pathol. 2011 Apr;24(4):512-21. doi: 10.1038/modpathol.2010.215. Epub 2010 Dec 3.

3.

Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Köbel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL, Vierkant RA, Cunningham JM, Chow C, Ness RB, Moysich K, Edwards R, Modugno F, Bunker C, Wozniak EL, Benjamin E, Gayther SA, Gentry-Maharaj A, Menon U, Gilks CB, Huntsman DG, Ramus SJ, Goode EL; Ovarian Tumor Tissue Analysis consortium..

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1677-86. doi: 10.1158/1055-9965.EPI-13-0391. Epub 2013 Jul 23.

4.

Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry.

Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck A, Tolf A, Gilks CB, Carlson JW.

Histopathology. 2014 Jun;64(7):1004-13. doi: 10.1111/his.12349. Epub 2014 Mar 7.

PMID:
24329781
5.

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D.

PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.

6.

Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.

McCluggage WG, Young RH.

Semin Diagn Pathol. 2005 Feb;22(1):3-32. Review.

PMID:
16512597
7.

The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists?

Tyler CW Jr, Lee NC, Robboy SJ, Kurman RJ, Paris AL, Wingo PA, Williamson GD.

Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):65-70.

PMID:
1986629
8.

Design of a bio-mathematical prediction model using serum tumor markers and immunohistochemistry in peritoneal carcinomatosis with ovarian involvement: a pilot study.

Khatami Z, Cross P, Stevenson MR, Naik R.

Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1258-63. Epub 2007 Apr 13.

PMID:
17433061
9.

Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma.

Cheng L, Zhang S, Talerman A, Roth LM.

Hum Pathol. 2010 May;41(5):716-23. doi: 10.1016/j.humpath.2009.10.016. Epub 2010 Jan 21.

PMID:
20096442
10.

Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.

Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, Lee S, Lee C, Ko JJ, An HJ.

J Proteome Res. 2010 Jan;9(1):451-7. doi: 10.1021/pr900811x.

PMID:
19902980
11.

Clinical factors and biomarkers in ovarian tumors development.

Vrabie CD, Petrescu A, Waller M, Dina I.

Rom J Morphol Embryol. 2008;49(3):327-38.

12.

Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.

Kao YC, Lin MC, Lin WC, Jeng YM, Mao TL.

Histopathology. 2012 Nov;61(5):760-8. doi: 10.1111/j.1365-2559.2012.04267.x. Epub 2012 Jul 2.

PMID:
22747504
13.

Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.

Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, Abdulkarim S, Leung S, Duggan MA, Fontaine D, Parker R, Huntsman DG, Gilks CB.

Am J Surg Pathol. 2010 Jul;34(7):984-93. doi: 10.1097/PAS.0b013e3181e1a3bb.

PMID:
20505499
14.

Ovarian carcinoma pathology and genetics: recent advances.

Gilks CB, Prat J.

Hum Pathol. 2009 Sep;40(9):1213-23. doi: 10.1016/j.humpath.2009.04.017. Epub 2009 Jun 24. Review.

PMID:
19552940
15.

Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.

Lu R, Sun M, Feng J, Gao X, Guo L.

BMC Cancer. 2011 Jun 25;11:270. doi: 10.1186/1471-2407-11-270.

16.

Value of immunohistochemistry in confirming undifferentiated ovarian carcinomas.

Georgescu CV, Florescu M, Simionescu C.

Rom J Morphol Embryol. 1999-2004;45:133-42.

PMID:
15847387
17.

Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

Sandeck HP, Røe OD, Kjærheim K, Willén H, Larsson E.

Diagn Pathol. 2010 Jul 6;5:47. doi: 10.1186/1746-1596-5-47.

18.

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.

Prentice LM, Klausen C, Kalloger S, Köbel M, McKinney S, Santos JL, Kenney C, Mehl E, Gilks CB, Leung P, Swenerton K, Huntsman DG, Aparicio SA.

BMC Med. 2007 Nov 15;5:33.

19.

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB.

Mod Pathol. 2009 Mar;22(3):469-75. doi: 10.1038/modpathol.2008.206. Epub 2009 Jan 9.

20.

Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

McCluggage WG.

Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Review.

PMID:
21716157

Supplemental Content

Support Center